INDIVIOR PHARMACEUTICALS INC (INDV) Stock Fundamental Analysis

NASDAQ:INDV • US45579U1097

32.72 USD
-0.99 (-2.94%)
At close: Feb 27, 2026
32.72 USD
0 (0%)
After Hours: 2/27/2026, 8:11:13 PM
Fundamental Rating

5

Overall INDV gets a fundamental rating of 5 out of 10. We evaluated INDV against 193 industry peers in the Pharmaceuticals industry. While INDV has a great profitability rating, there are some minor concerns on its financial health. INDV has a bad growth rate and is valued cheaply.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • INDV had positive earnings in the past year.
  • INDV had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: INDV reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: INDV reported negative operating cash flow in multiple years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • INDV has a better Return On Assets (8.62%) than 89.64% of its industry peers.
  • With an excellent Return On Invested Capital value of 50.62%, INDV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for INDV is significantly above the industry average of 12.93%.
  • The 3 year average ROIC (43.06%) for INDV is below the current ROIC(50.62%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROIC 50.62%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • INDV's Profit Margin of 10.34% is amongst the best of the industry. INDV outperforms 84.46% of its industry peers.
  • INDV's Profit Margin has declined in the last couple of years.
  • INDV has a better Operating Margin (24.49%) than 92.23% of its industry peers.
  • In the last couple of years the Operating Margin of INDV has remained more or less at the same level.
  • The Gross Margin of INDV (85.51%) is better than 89.12% of its industry peers.
  • INDV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), INDV is creating value.
  • INDV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 2.64 indicates that INDV is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • INDV has a better Altman-Z score (2.64) than 68.39% of its industry peers.
  • INDV has a debt to FCF ratio of 2.68. This is a good value and a sign of high solvency as INDV would need 2.68 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 2.68, INDV belongs to the best of the industry, outperforming 93.26% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Altman-Z 2.64
ROIC/WACC5.42
WACC9.34%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 0.96 indicates that INDV may have some problems paying its short term obligations.
  • INDV's Current ratio of 0.96 is on the low side compared to the rest of the industry. INDV is outperformed by 84.97% of its industry peers.
  • A Quick Ratio of 0.79 indicates that INDV may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.79, INDV is doing worse than 80.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.79
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 459.09% over the past year.
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%

3.2 Future

  • The Earnings Per Share is expected to decrease by -3.07% on average over the next years.
  • Based on estimates for the next years, INDV will show a small growth in Revenue. The Revenue will grow by 0.79% on average per year.
EPS Next Y22.44%
EPS Next 2Y15.88%
EPS Next 3Y-10.86%
EPS Next 5Y-3.07%
Revenue Next Year-3.87%
Revenue Next 2Y0.57%
Revenue Next 3Y-0.58%
Revenue Next 5Y0.79%

3.3 Evolution

INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 2 3

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 13.30, INDV is valued correctly.
  • Compared to the rest of the industry, the Price/Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 88.60% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.07, INDV is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 10.86, the valuation of INDV can be described as very reasonable.
  • 87.56% of the companies in the same industry are more expensive than INDV, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.05, INDV is valued rather cheaply.
Industry RankSector Rank
PE 13.3
Fwd PE 10.86
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, INDV is valued cheaply inside the industry as 84.46% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 81.35% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 34.04
EV/EBITDA 12.58
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • INDV has a very decent profitability rating, which may justify a higher PE ratio.
  • INDV's earnings are expected to decrease with -10.86% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y15.88%
EPS Next 3Y-10.86%

0

5. Dividend

5.1 Amount

  • No dividends for INDV!.
Industry RankSector Rank
Dividend Yield 0%

INDIVIOR PHARMACEUTICALS INC

NASDAQ:INDV (2/27/2026, 8:11:13 PM)

After market: 32.72 0 (0%)

32.72

-0.99 (-2.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)04-22
Inst Owners92.33%
Inst Owner Change-70.46%
Ins Owners3.78%
Ins Owner Change31.01%
Market Cap4.09B
Revenue(TTM)N/A
Net Income(TTM)122.00M
Analysts84.62
Price Target46.48 (42.05%)
Short Float %10.17%
Short Ratio5.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.33%
PT rev (3m)24.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.31%
EPS NY rev (1m)0%
EPS NY rev (3m)79.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.81%
Valuation
Industry RankSector Rank
PE 13.3
Fwd PE 10.86
P/S 3.46
P/FCF 34.04
P/OCF 22.69
P/B N/A
P/tB N/A
EV/EBITDA 12.58
EPS(TTM)2.46
EY7.52%
EPS(NY)3.01
Fwd EY9.21%
FCF(TTM)0.96
FCFY2.94%
OCF(TTM)1.44
OCFY4.41%
SpS9.45
BVpS-1.66
TBVpS-1.67
PEG (NY)0.59
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROCE 64.08%
ROIC 50.62%
ROICexc 3805.17%
ROICexgc 5707.75%
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
FCFM 10.17%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Debt/EBITDA 0.97
Cap/Depr 230.77%
Cap/Sales 5.08%
Interest Coverage 250
Cash Conversion 57.14%
Profit Quality 98.36%
Current Ratio 0.96
Quick Ratio 0.79
Altman-Z 2.64
F-Score8
WACC9.34%
ROIC/WACC5.42
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
EPS Next Y22.44%
EPS Next 2Y15.88%
EPS Next 3Y-10.86%
EPS Next 5Y-3.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%
Revenue Next Year-3.87%
Revenue Next 2Y0.57%
Revenue Next 3Y-0.58%
Revenue Next 5Y0.79%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1050.98%
EBIT Next 3Y148.27%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%

INDIVIOR PHARMACEUTICALS INC / INDV FAQ

What is the fundamental rating for INDV stock?

ChartMill assigns a fundamental rating of 5 / 10 to INDV.


What is the valuation status of INDIVIOR PHARMACEUTICALS INC (INDV) stock?

ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.


What is the profitability of INDV stock?

INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.


How financially healthy is INDIVIOR PHARMACEUTICALS INC?

The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.


Is the dividend of INDIVIOR PHARMACEUTICALS INC sustainable?

The dividend rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 0 / 10 and the dividend payout ratio is 0%.